Report of the European respiratory society/European cystic fibrosis society task force on the care of adults with cystic fibrosis

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 420-428

  Elborn, J Stuart ^a   Bell, Scott C ^b   Madge, Susan L ^c   Burgel, Pierre Regis ^d   Castellani, Carlo ^e   Conway, Steven ^f   De Rijcke, Karleen ^g   Dembski, Birgit ^h   Drevinek, Pavel ⁱ   Heijerman, Harry G M ^j   Innes, J Alistair ^k   Lindblad, Anders ^l   Marshall, Bruce ^m   Olesen, Hanne V ⁿ   Reimann, Andreas L ^o   Solé, Ampara ^p   Viviani, Laura ^q   Wagner, Thomas O F ^r   Welte, Tobias ^s   Blasi, Francesco ^q  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d université Paris Cité   (France)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^g UZ Brussel   (Belgium)

^h Mukoviszidose eV   (Germany)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j HAGA HOSPITAL   (Netherlands)

^k WESTERN GENERAL HOSPITAL   (United Kingdom)

^l QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^m CYSTIC FIBROSIS FOUNDATION   (United States)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o Mukoviszidose Institut gGmbH   (Germany)

^p HOSPITAL UNIVERSITARIO LA FE   (Spain)

^q UNIVERSITY OF MILAN   (Italy)

^r GOETHE UNIVERSITY   (Germany)

^s HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ARTICLE; CYSTIC FIBROSIS; DELAYED DIAGNOSIS; FORECASTING; HEALTH CENTER; HUMAN; LUNG TRANSPLANTATION; MANPOWER PLANNING; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SOCIAL PSYCHOLOGY; SURVIVAL; TERMINAL CARE; TRANSITION TO ADULT CARE; ADVISORY COMMITTEE; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; EDUCATION; EUROPE; HEALTH CARE PLANNING; HEALTH SERVICE; MANPOWER; ORGANIZATION AND MANAGEMENT; PSYCHOLOGY; PULMONOLOGY; SOCIAL SUPPORT;

ADULT; ADVISORY COMMITTEES; CYSTIC FIBROSIS; DISEASE MANAGEMENT; EUROPE; HEALTH PLANNING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LUNG TRANSPLANTATION; PATIENT COMPLIANCE; PULMONARY MEDICINE; SOCIAL SUPPORT; SOCIETIES, MEDICAL; TERMINAL CARE; TRANSITION TO ADULT CARE;

EID: 84958048635     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00592-2015     Document Type: Article

References (59)

1. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008.
2. Simmonds NJ. Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev 2013; 14: Suppl. 1, 6-9.
3. Parkins MD, Parkins VM, Rendall JC, et al. Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Ther Adv Respir Dis 2011; 5: 105-119.
4. Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-821.
5. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303: 2386-2392.
6. Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010; 9: 104-109.
7. Jennings MT, Riekert KA, Boyle MP. Update on key emerging challenges in cystic fibrosis. Med Princ Pract 2014; 23: 393-402.
8. Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. J Cyst Fibros 2014; 13: Suppl. 1, S3-S22.
9. Simmonds NJ, Macneill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010; 36: 1277-1283.
10. Burgel PR, Bellis G, Olesen H, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46: 133-141.
11. McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 11 902-910.
12. De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014; 13 674-680.
13. Wainwright CE. Ivacaftor for patients with cystic fibrosis. Expert Rev Respir Med 2014; 8: 533-538.
14. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
15. Plant BJ, Goss CH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1: 164-174.
16. Roehmel JF, Schwarz C, Mehl A, et al. Hypersensitivity to antibiotics in patients with cystic fibrosis. J Cyst Fibros 2014; 13: 205-211.
17. Gory I, Brown G, Wilson J, et al. Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case-control study. Scand J Gastroenterol 2014; 49: 1230-1236.
18. Maisonneuve P, Marshall BC, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122-129.
19. Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: a center-based analysis. Pediatr Pulmonol 2015; 50: 35-44.
20. Buehler T, Steinmann M, Singer F, et al. Increased arterial stiffness in children with cystic fibrosis. Eur Respir J 2012; 39: 1536-1537.
21. Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13: Suppl. 1, S23-S42.
22. Stern M, Bertrand DP, Bignamini E, et al. European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. J Cyst Fibros 2014; 13: Suppl. 1, S43-S59.
23. Tuchman L, Schwartz M. Health outcomes associated with transition from pediatric to adult cystic fibrosis care. Pediatrics 2013; 132: 847.
24. Nasr SZ. Cystic fibrosis in adolescents and young adults. Adolesc Med 2000; 11: 589-603.
25. Arias Llorente RP, Bousono Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008; 7: 359-367.
26. O'Donohoe R, Fullen BM. Adherence of subjects with cystic fibrosis to their home program: a systematic review. Respir Care 2014; 59: 1731-1746.
27. Sawicki GS, Heller KS, Demars N, et al. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol 2015; 50: 127-136.
28. Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax 2014; 69: 1090-1097.
29. Bolyard DR. Sexuality and cystic fibrosis. MCN Am J Matern Child Nurs 2001; 26: 39-41.
30. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011; 183: 1463-1471.
31. Sawicki GS, Ren CL, Konstan MW, et al. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros 2013; 12: 461-467.
32. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014; 146: 142-151.
33. Duff AJ, Latchford GJ. Motivational interviewing for adherence problems in cystic fibrosis. Pediatr Pulmonol 2010; 45: 211-220.
34. Smith B, Goldbeck L, Georgiopoulos AM. Screening and assessment: psycological intervention, pharmacologicial interventions. Ped Pulmonol 2014; 49: 171-172.
35. Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in cystic fibrosis. Pediatr Clin North Am 2011; 58: 865-885.
36. Goldbeck L, Fidika A, Herle M, et al. Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database Syst Rev 2014; 6: CD003148.
37. Dill EJ, Dawson R, Sellers DE, et al. Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest 2013; 144: 981-989.
38. Schram CA. Atypical cystic fibrosis: identification in the primary care setting. Can Fam Physician 2012; 58: 1341-1345.
39. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10: Suppl. 2, S86-102.
40. Corris PA. Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2013; 34: 297-304.
41. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-1555.
42. Lucangelo U, Del Sorbo L, Boffini M, et al. Protective ventilation for lung transplantation. Curr Opin Anaesthesiol 2012; 25: 170-174.
43. Gattinoni L, Carlesso E, Langer T. Clinical review: extracorporeal membrane oxygenation. Crit Care 2011; 15: 243.
44. Hirche TO, Knoop C, Hebestreit H, et al. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014; 2014: 621342.
45. Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10: 253-257.
46. Sands D, Repetto T, Dupont LJ, et al. End of life care for patients with cystic fibrosis. J Cyst Fibros 2011; 10: S37-S44.
47. McDonald CM, Haberman D, Brown N. Self-efficacy: empowering parents of children with cystic fibrosis. J Cyst Fibros 2013; 12: 538-543.
48. Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PLoS One 2013; 8: e73322.
49. Gleeson H, Turner G. Transition to adult services. Arch Dis Child Educ Pract Ed 2012; 97: 86-92.
50. Madge S, Bryon M. A model for transition from pediatric to adult care of care in cystic fibrosis. J Pediatr Nurs 2002; 17: 283-288.
51. Flume PA, Taylor LA, Anderson DL, et al. Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol 2004; 37: 4-7.
52. Dassios T. Determinants of respiratory pump function in patients with cystic fibrosis. Paediatr Respir Rev 2015; 16: 75-79.
53. Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35: Suppl. 1, S1-S67.
54. Doull I, Evans H, South and Mid Wales Paediatric Cystic Fibrosis Network. Full, shared and hybrid paediatric care for cystic fibrosis in South and Mid Wales. Arch Dis Child 2012; 97: 17-20.
55. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis - provision of care. J Cyst Fibros 2009; 8: 348-355.
56. Bella S, Murgia F, Cotognini C, et al. Program of home telemonitoring in patients with cystic fibrosis over a period of 2 years: a contribution to the rationalization of care. Clin Ter 2013; 164: e313-e317.
57. Cox NS, Alison JA, Rasekaba T, et al. Telehealth in cystic fibrosis: a systematic review. J Telemed Telecare 2012; 18: 72-78.
58. Bella S, Murgia F, Cotognini C, et al. Program of home telemonitoring in patients with cystic fibrosis over a period of 2 years: a contribution to the rationalization of care. Clin Ter 2013; 164: e313-e317.
59. Harmonised Education in Respiratory Medicine for European Specialists. Accreditation process. http://hermes. ersnet.org/accreditation/accreditation-process/